FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891953730> ?p ?o ?g. }

• W2891953730 endingPage "9534" @default.
• W2891953730 startingPage "9534" @default.
• W2891953730 abstract "9534 Background: SD-101 is a synthetic CpG TLR9 agonist. Pembrolizumab is a PD-1 inhibitor. SYNERGY-001/KEYNOTE-184 assesses the safety and preliminary efficacy of the combination of SD-101 and pembrolizumab in patients naïve to anti-PD-1/L1 therapy with unresectable stage IIIC-IV melanoma. Methods: SD-101 was evaluated as 2 mg/lesion injected into 1 to 4 lesions and 8 mg/lesion in 1 lesion as 4 weekly doses followed by 7 doses Q3W. Pembrolizumab was administered as 200 mg IV Q3W. CT scans were performed every 9 weeks. Responses were assessed per investigator using RECIST v1.1. Responses and post-hoc Kaplan-Meier analyses of PFS in the ITT population were compared for patients who received 2 mg/lesion with 8 mg/lesion. Results: 86 patients (2 mg: N = 45; 8 mg: N = 41) have been enrolled with similar baseline characteristics: median age = 66 years; male = 67%; ECOG stage 0 = 67%; disease stage: IIIC = 21%; IVM1a/b = 50%; IVM1c = 28%; LDH ≤ ULN = 71%; treatment naïve = 73%. Median follow up to date is 8.1 months in 2 mg group and 8.3 months in 8 mg group. SD-101 safety profile comprises flu-like symptoms with most frequent grade ≥3 SD-101-related AEs of headache (7%), fatigue (7%), malaise (5%), myalgia (4%), and chills (4%). Immune-related AEs were reported in 19%. ORR in 2 mg group = 71% (95% CI: 57, 82) (CR: 13%) and in 8 mg group = 49% (95% CI: 33, 65) (CR: 7%) with responses in both injected and non-injected lesions, including visceral. DOR = not reached (NR) in either group. ORR by baseline PD-L1 expression in 62 patients, 53% of whom were PD-L1 positive: 2 mg = 80%/79% (PD-L1 positive/negative); 8 mg = 62%/40% (PD-L1 positive/negative). PFS was higher in 2 mg group with median PFS in 2 mg = NR (95% CI: Not estimable [NE], NE) and in 8 mg = 10.4 months (95% CI: 4.2, NE), HR = 0.45 (95% CI: 0.21, 0.98), p = 0.036. 6 month PFS rate in 2 mg = 81% and in 8 mg = 60%. 6 month OS rate in 2 mg = 98% and in 8 mg = 92%. Conclusions: The TLR9 innate immune stimulant, SD-101, in combination with pembrolizumab has been well-tolerated, and is showing promising high response rates and PFS, regardless of PD-L1 expression, particularly in patients who received 2 mg SD-101. Clinical trial information: NCT02521870." @default.
• W2891953730 created "2018-09-27" @default.
• W2891953730 creator A5001488019 @default.
• W2891953730 creator A5015591858 @default.
• W2891953730 creator A5021505713 @default.
• W2891953730 creator A5022775074 @default.
• W2891953730 creator A5029723783 @default.
• W2891953730 creator A5029783882 @default.
• W2891953730 creator A5032499433 @default.
• W2891953730 creator A5036004013 @default.
• W2891953730 creator A5038887077 @default.
• W2891953730 creator A5053441903 @default.
• W2891953730 creator A5056083434 @default.
• W2891953730 creator A5064284912 @default.
• W2891953730 creator A5070016877 @default.
• W2891953730 creator A5070553718 @default.
• W2891953730 creator A5070576000 @default.
• W2891953730 creator A5075092848 @default.
• W2891953730 creator A5078912565 @default.
• W2891953730 creator A5083745558 @default.
• W2891953730 creator A5084480627 @default.
• W2891953730 creator A5088232810 @default.
• W2891953730 date "2019-05-20" @default.
• W2891953730 modified "2023-09-23" @default.
• W2891953730 title "Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy." @default.
• W2891953730 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.9534" @default.
• W2891953730 hasPublicationYear "2019" @default.
• W2891953730 type Work @default.
• W2891953730 sameAs 2891953730 @default.
• W2891953730 citedByCount "24" @default.
• W2891953730 countsByYear W28919537302019 @default.
• W2891953730 countsByYear W28919537302020 @default.
• W2891953730 countsByYear W28919537302021 @default.
• W2891953730 countsByYear W28919537302022 @default.
• W2891953730 countsByYear W28919537302023 @default.
• W2891953730 crossrefType "journal-article" @default.
• W2891953730 hasAuthorship W2891953730A5001488019 @default.
• W2891953730 hasAuthorship W2891953730A5015591858 @default.
• W2891953730 hasAuthorship W2891953730A5021505713 @default.
• W2891953730 hasAuthorship W2891953730A5022775074 @default.
• W2891953730 hasAuthorship W2891953730A5029723783 @default.
• W2891953730 hasAuthorship W2891953730A5029783882 @default.
• W2891953730 hasAuthorship W2891953730A5032499433 @default.
• W2891953730 hasAuthorship W2891953730A5036004013 @default.
• W2891953730 hasAuthorship W2891953730A5038887077 @default.
• W2891953730 hasAuthorship W2891953730A5053441903 @default.
• W2891953730 hasAuthorship W2891953730A5056083434 @default.
• W2891953730 hasAuthorship W2891953730A5064284912 @default.
• W2891953730 hasAuthorship W2891953730A5070016877 @default.
• W2891953730 hasAuthorship W2891953730A5070553718 @default.
• W2891953730 hasAuthorship W2891953730A5070576000 @default.
• W2891953730 hasAuthorship W2891953730A5075092848 @default.
• W2891953730 hasAuthorship W2891953730A5078912565 @default.
• W2891953730 hasAuthorship W2891953730A5083745558 @default.
• W2891953730 hasAuthorship W2891953730A5084480627 @default.
• W2891953730 hasAuthorship W2891953730A5088232810 @default.
• W2891953730 hasConcept C121608353 @default.
• W2891953730 hasConcept C126322002 @default.
• W2891953730 hasConcept C141071460 @default.
• W2891953730 hasConcept C197934379 @default.
• W2891953730 hasConcept C2777701055 @default.
• W2891953730 hasConcept C2778375690 @default.
• W2891953730 hasConcept C2778594517 @default.
• W2891953730 hasConcept C2778616394 @default.
• W2891953730 hasConcept C2780057760 @default.
• W2891953730 hasConcept C2781156865 @default.
• W2891953730 hasConcept C71924100 @default.
• W2891953730 hasConcept C90924648 @default.
• W2891953730 hasConceptScore W2891953730C121608353 @default.
• W2891953730 hasConceptScore W2891953730C126322002 @default.
• W2891953730 hasConceptScore W2891953730C141071460 @default.
• W2891953730 hasConceptScore W2891953730C197934379 @default.
• W2891953730 hasConceptScore W2891953730C2777701055 @default.
• W2891953730 hasConceptScore W2891953730C2778375690 @default.
• W2891953730 hasConceptScore W2891953730C2778594517 @default.
• W2891953730 hasConceptScore W2891953730C2778616394 @default.
• W2891953730 hasConceptScore W2891953730C2780057760 @default.
• W2891953730 hasConceptScore W2891953730C2781156865 @default.
• W2891953730 hasConceptScore W2891953730C71924100 @default.
• W2891953730 hasConceptScore W2891953730C90924648 @default.
• W2891953730 hasIssue "15_suppl" @default.
• W2891953730 hasLocation W28919537301 @default.
• W2891953730 hasOpenAccess W2891953730 @default.
• W2891953730 hasPrimaryLocation W28919537301 @default.
• W2891953730 hasRelatedWork W1970508517 @default.
• W2891953730 hasRelatedWork W2357423789 @default.
• W2891953730 hasRelatedWork W2981540799 @default.
• W2891953730 hasRelatedWork W3035098496 @default.
• W2891953730 hasRelatedWork W3172600265 @default.
• W2891953730 hasRelatedWork W3215733694 @default.
• W2891953730 hasRelatedWork W4200350460 @default.
• W2891953730 hasRelatedWork W4283518051 @default.
• W2891953730 hasRelatedWork W4284891694 @default.
• W2891953730 hasRelatedWork W4327682587 @default.
• W2891953730 hasVolume "37" @default.
• W2891953730 isParatext "false" @default.
• W2891953730 isRetracted "false" @default.
• W2891953730 magId "2891953730" @default.

• next